Truist Securities analyst Danielle Brill upgraded Biogen (NASDAQ: BIIB) from Hold to Buy with a price target of $235.00.

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $199.15 yesterday.